Flash e-reader

 Go to e-reader chapter








PDF FormatRequires Adobe Acrobat Reader

Table 11.6h

Persistency of Discharge Regimen by Follow-up Period, 2004 to 2008

Recipients with Heart Transplants

  Year of Transplant
2004 2005 2006 2007 2008
Discharge Regimen (w/ or w/o Steroid Use) CyA+Aza At Discharge (N) 84 48 43 30 17
At Discharge (%) 100.0% 100.0% 100.0% 100.0% 100.0%
1 Year PostTx (%) 63.1% 76.7% 74.4% 58.6% 50.7%
2 Years PostTx (%) 41.3% 41.7% 46.5% 25.6% -
3 Years PostTx (%) 30.0% 30.2% 44.2% 25.6% -
CyA+MMF At Discharge (N) 752 637 612 547 415
At Discharge (%) 100.0% 100.0% 100.0% 100.0% 100.0%
1 Year PostTx (%) 77.9% 81.9% 81.0% 78.8% 73.4%
2 Years PostTx (%) 61.3% 65.4% 66.4% 63.5% 57.6%
3 Years PostTx (%) 52.3% 55.9% 56.5% 51.4% -
CyA+Siro At Discharge (N) 2 2 2 - 2
At Discharge (%) 100.0% 100.0% 100.0% - 100.0%
1 Year PostTx (%) 50.0% 100.0% 50.0% - 50.0%
2 Years PostTx (%) 50.0% 0.0% 50.0% - 0.0%
3 Years PostTx (%) 50.0% 0.0% 50.0% - 0.0%
Siro+MMF At Discharge (N) 24 17 25 7 6
At Discharge (%) 100.0% 100.0% 100.0% 100.0% 100.0%
1 Year PostTx (%) 75.0% 64.7% 87.5% 57.1% 41.7%
2 Years PostTx (%) 58.3% 64.7% 75.0% 57.1% -
3 Years PostTx (%) 54.2% 47.1% 62.5% 57.1% -
Tac+Aza At Discharge (N) 23 20 27 20 28
At Discharge (%) 100.0% 100.0% 100.0% 100.0% 100.0%
1 Year PostTx (%) 78.3% 60.0% 77.8% 72.2% 63.0%
2 Years PostTx (%) 60.9% 45.0% 59.3% 58.3% 63.0%
3 Years PostTx (%) 47.8% 39.4% 59.3% 58.3% -
Tac+MMF At Discharge (N) 724 941 1,059 1,237 1,357
At Discharge (%) 100.0% 100.0% 100.0% 100.0% 100.0%
1 Year PostTx (%) 83.9% 86.1% 87.6% 86.0% 82.9%
2 Years PostTx (%) 73.5% 75.7% 77.5% 74.2% 69.5%
3 Years PostTx (%) 66.5% 70.6% 70.3% 68.3% -
Tac+Siro At Discharge (N) 19 23 26 7 5
At Discharge (%) 100.0% 100.0% 100.0% 100.0% 100.0%
1 Year PostTx (%) 55.7% 82.6% 69.2% 85.7% 80.0%
2 Years PostTx (%) 44.6% 69.6% 61.5% 64.3% 80.0%
3 Years PostTx (%) 33.4% 60.9% 61.5% 64.3% -


Source: OPTN/SRTR Data as of October 1, 2010.

Regimen change is defined as being on different drug combination at follow-up comparing to discharge, or indication of conflicting regimen

(CyA vs. Tac; MMF/MPA vs. Aza; Siro vs. Evero) during follow-up period, or graft failure/death. Addition or deletion of steroids is not considered a regimen change.&

Rates are calculated for the most common discharge regimens.

CyA: Cyclosporine; Tac: Tacrolimus; MMF: Include MMF(Mycophenolate Mofetil) and MPA(Mycophenolate Sodium); Aza: Azathioprine; Siro: Sirolimus.

See Technical Notes for further details.